Medialipide

Soya-Bean Oil Refined, Medium Chain Triglycerides, the active ingredient in Medialipide, is an excipient presented as an intravenous solution for intravenous use. It provides a source of medium-chain fatty acids and serves as a lipid carrier in parenteral formulations.

GNH USA supplies Medialipide as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Medialipide, containing medium-chain triglycerides, is used as a lipid component in intravenous nutrition and drug delivery systems.

Parenteral nutrition: supplies calories and essential fatty acids for patients requiring intravenous feeding. Lipid-based drug formulations: acts as a solubilizing vehicle for fat‑soluble medications administered intravenously. Organ transplantation support: provides an energy substrate in post‑operative IV regimens.

Medialipide may be associated with several adverse reactions when administered intravenously.

Common Side Effects: - Hypertriglyceridemia: mild elevation of serum triglyceride levels. - Infusion site reactions: erythema, warmth, or mild pain at the catheter site. - Transient fever: low‑grade temperature rise during infusion. - Nausea or mild gastrointestinal discomfort. - Headache: occasional mild headache during or after infusion. - Allergic rash: skin erythema or urticaria.

Serious or Rare Side Effects: - Anaphylaxis: severe hypersensitivity requiring immediate medical intervention. - Fat overload syndrome: accumulation of lipids leading to organ dysfunction. - Hepatic dysfunction: elevated liver enzymes or hepatic steatosis. - Acute pancreatitis: inflammation of the pancreas. - Embolism: lipid emboli causing respiratory or circulatory compromise. - Severe hypotension: sudden drop in blood pressure during infusion.

When using Medialipide, clinicians should observe specific safety measures.

Patient assessment: evaluate lipid tolerance and baseline triglyceride levels. Monitoring: check serum triglycerides and liver enzymes during therapy. Allergy screening: assess for soy or lipid emulsion hypersensitivity. Dose adjustment: modify in patients with impaired fatty acid oxidation. Compatibility: verify compatibility with co‑administered drugs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Medialipide can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Propofol: additive lipid load may cause fat overload. - Corticosteroids: can increase triglyceride concentrations. - Heparin: may potentiate hypertriglyceridemia.

Moderate Interactions (Monitor Closely): - Vincristine: lipid emulsion may alter drug distribution. - Cyclosporine: monitor liver function due to combined hepatic load. - Statins: watch for additive hepatic effects.